Available Technology
A method for producing partially deglycosylated HIV-1 envelope glycoproteins through site-directed mutagenesis
Technology:
Compositions of deglycosylated HIV-1 glycoproteins and administration to mammals for antibody production
Markets Addressed
The invention provides for compositions of deglycosylated HIV-1 glycoproteins and for their administration to mammals for antibody production.
Innovations and Advantages
This invention describes a method for producing partially deglycosylated HIV-1 envelope glycoproteins through site-directed mutagenesis. Removal of multiple carbohydrate residues by mutation of their consensus N-linkage sites exposes gp160/gp120 protein domains to the host immune system and may lead to enhanced immune response. Such mutated derivations of gp160/gp120 retain normal structure and function, as measured by infectivity of virions bearing the mutated proteins.
Additional Information
Intellectual Property Status: Issued U.S. patent nos.: 6,103,238
Tweet
Inventor(s):
Essex, Myron E
Lee, Chun-nan
Lee, Tun-Hou
Lee, Woan-Ruoh
Categories:
For further information, please contact:
Debra Peattie, Director of Business Development
(617) 495-3067
Reference Harvard Case #0806